- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01078389
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Gout is caused by high levels of uric acid in the body, and is associated with a broad range of comorbidities including heart disease, chronic kidney disease and additional risk factors like obesity and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form from supersaturated body fluids and settle in joints and other organs. Urate-lowering therapy is used to treat hyperuricemia in patients with gout.
Current treatments focus on initiating urate-lowering therapy in hyperuricemic gout patients who have experienced multiple acute gout flares within the past year. However, joint damage caused by crystal deposition may occur much earlier than previously considered. Monosodium urate crystals have been found present in the joints of people with hyperuricemia who do not have any symptoms. The presence of monosodium urate crystals would indicate that after the crystals form, they stay within the joint if serum urate levels are not reduced. Lowering uric acid levels and maintaining them may reduce acute gout flare episodes and possibly halt or reduce joint damage in patients with gout.
This study will evaluate the effect of febuxostat on joint damage in hyperuricemic patients with early gout. All patients will receive gout flare prophylaxis for the first 6 months of the study. Gout flares may also be treated throughout the study.
A variety of imaging techniques are in use to evaluate gout. Plain radiographs (x-rays), Magnetic Resonance Imaging (MRI) and Dual Energy Computed Tomography (DECT) will be utilized in this study. The modified Sharp/Van Der Heijde scoring method (named after Drs. Sharp and Van Der Heijde) for assessment of x-rays has been validated in patients with chronic gout and will be used in this study for evaluating erosion and joint space narrowing. Participants are expected to have 15 visits which will include plain radiographic examinations at 5 visits, 3 Magnetic Resonance Imaging (MRI) examinations and 3 DECT procedures at selected sites.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Mesa, Arizona, Estados Unidos
-
Tucson, Arizona, Estados Unidos
-
-
California
-
Burbank, California, Estados Unidos
-
Carmichael, California, Estados Unidos
-
Costa Mesa, California, Estados Unidos
-
Irvine, California, Estados Unidos
-
Orange, California, Estados Unidos
-
Rancho Cucamonga, California, Estados Unidos
-
San Diego, California, Estados Unidos
-
San Luis Obispo, California, Estados Unidos
-
-
Connecticut
-
Trumbull, Connecticut, Estados Unidos
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos
-
Daytona Beach, Florida, Estados Unidos
-
Fort Lauderdale, Florida, Estados Unidos
-
Hialeah, Florida, Estados Unidos
-
Miami, Florida, Estados Unidos
-
Sanford, Florida, Estados Unidos
-
Tampa, Florida, Estados Unidos
-
Winter Park, Florida, Estados Unidos
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos
-
-
Illinois
-
Arlington Heights, Illinois, Estados Unidos
-
-
Indiana
-
Avon, Indiana, Estados Unidos
-
Greenfield, Indiana, Estados Unidos
-
-
Kansas
-
Wichita, Kansas, Estados Unidos
-
-
Maine
-
Rockport, Maine, Estados Unidos
-
-
Minnesota
-
Chaska, Minnesota, Estados Unidos
-
-
Mississippi
-
Belzoni, Mississippi, Estados Unidos
-
Olive Branch, Mississippi, Estados Unidos
-
-
Montana
-
Billings, Montana, Estados Unidos
-
Missoula, Montana, Estados Unidos
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos
-
-
Nevada
-
Henderson, Nevada, Estados Unidos
-
Las Vegas, Nevada, Estados Unidos
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos
-
Lenoir, North Carolina, Estados Unidos
-
Shelby, North Carolina, Estados Unidos
-
-
Ohio
-
Dayton, Ohio, Estados Unidos
-
Franklin, Ohio, Estados Unidos
-
Willoughby Hills, Ohio, Estados Unidos
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos
-
-
Oregon
-
Eugene, Oregon, Estados Unidos
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Estados Unidos
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos
-
-
Tennessee
-
Kingsport, Tennessee, Estados Unidos
-
-
Texas
-
Austin, Texas, Estados Unidos
-
Houston, Texas, Estados Unidos
-
San Antonio, Texas, Estados Unidos
-
Southlake, Texas, Estados Unidos
-
Sugar Land, Texas, Estados Unidos
-
-
Virginia
-
Arlington, Virginia, Estados Unidos
-
Burke, Virginia, Estados Unidos
-
Manassas, Virginia, Estados Unidos
-
-
Wisconsin
-
Kenosha, Wisconsin, Estados Unidos
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- The participant, or the participant's legally acceptable representative, signs a written informed consent form/Health Insurance Portability & Accountability Act (HIPAA) Authorization prior to the initiation of any study procedures.
Must have a history or presence of gout defined as having one or more of the following conditions of the American Rheumatism Association (ARA) preliminary criteria for the diagnosis of gout
- A tophus proven to contain urate crystals by chemical or polarized light microscopic means and/or
- Characteristic urate crystals in the joint fluid and/or
History of at least 6 of the following clinical, laboratory and x-ray phenomena*: *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
- More than one attack of acute arthritis*
- maximum inflammation developed within 1 day
- monoarticular arthritis
- redness observed over joints
- first metatarsophalangeal joint painful or swollen
- unilateral first metatarsophalangeal joint attack
- unilateral tarsal joint attack
- tophus (proven or suspected)
- hyperuricemia
- asymmetric swelling within a joint on x-ray
- sub-cortical cysts without erosions on x-ray
- joint fluid culture negative for organisms during attacks
- *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
Is male and at least 18 years of age OR;
- Female ≥45 years of age and at least 2 years post-menopausal AND has a Follicle Stimulating Hormone (FSH) level ≥40 IU/L OR
- Female receiving hormone replacement therapy (HRT) must be ≥55 years of age (FSH level not required).
- Has hyperuricemia defined as serum Uric Acid (sUA) level ≥7.0 mg/dL at Screening.
- Has a history of ≤2 (1 or 2) flares. In participants with a history of 2 flares, must have had only one flare in any 12 month period. The primary affected joint will be based on the location of the first gout flare which must be located within right or left metatarsophalangeal (MTP), interphalangeal (IP), ankle, metacarpophalangeal (MCP), Proximal Inter-Phalangeal (PIP), or distal inter-phalangeal (DIP) joints prior to Screening.
- Is capable of understanding and complying with protocol requirements, including scheduled clinic procedures.
Exclusion Criteria:
- Previously on urate-lowering therapy (allopurinol, febuxostat or probenecid).
- Has secondary hyperuricemia (eg due to myeloproliferative disorder or organ transplant).
- Has a history of xanthinuria.
- Has a known hypersensitivity to any component of the febuxostat formulation.
- Has rheumatoid arthritis.
- Has active peptic ulcer disease.
- Has a history of cancer, except basal cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study medication.
- Has experienced either a myocardial infarction (MI) or stroke within 90 days prior to the Screening visit.
- Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 the upper limit of normal during the Screening period.
- Has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol at the discretion of the Investigator.
- Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse with 5 years prior to the Screening visit. Participant consumes >14 alcoholic beverages/week.
- Has received any investigational medicinal product within 30 days prior to the Screening visit. In addition, the participant has been previously randomized into this study and received at least one dose of double blind study drug treatment.
- Has an estimated Glomerular filtration rate (eGFR) <60 mL/min calculated using the Modification of Diet in Renal Disease (MDRD) formula by the Central Laboratory.
- Has a serum creatinine at Screening greater than 2.0 mg/dL.
- Has a known history of infection with hepatitis B, hepatitis C or human immunodeficiency virus.
- Is a study site employee, or is an immediate family member (ie, spouse, parent, child, and sibling) of a study site employee involved in conduct of this study.
- Is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent form is available.
- Is required to take excluded medications.
Magnetic Resolution Imaging:
- Has a known hypersensitivity to gadolinium
- Has history of severe asthma
- Has an electronically, magnetically or mechanically activated implanted device
- Has any object that could present a potential hazard or interfere with MRI interpretation secondary to the artifact (i.e. metallic foreign bodies)
- Has a significant medical condition considered by the Investigator (or radiologist) to interfere with the participant's ability to receive gadolinium (eg Sickle cell anemia).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Febuxostat 40 mg or 80 mg
Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
|
Cápsulas de Febuxostat
Outros nomes:
|
Comparador de Placebo: Placebo
Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
|
Febuxostat placebo-matching capsules
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint
Prazo: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst).
Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs
Prazo: Baseline and Month 24
|
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320.
Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208.
The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs
Prazo: Baseline and Month 24
|
Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint
Prazo: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS).
Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20.
Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst).
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint
Prazo: Baseline and Month 24
|
The single affected joint was defined as the joint with the history of the first acute gout flare.
Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method.
Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst).
The Erosion Score and the JSN Score were summed for the Total Score.
Higher scores indicated more joint damage.
A negative change from Baseline indicated improvement.
|
Baseline and Month 24
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TMX-67_204
- U1111-1113-8098 (Identificador de registro: WHO)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Joint Damage
-
Western University of Health SciencesConcluídoCharcot Articulação do PéEstados Unidos
-
University of UtahNational Cancer Institute (NCI)RecrutamentoFadiga | Estilo de vida sedentário | Carcinoma de Próstata Metastático | Câncer de Próstata Estágio IV AJCC (American Joint Committee on Cancer) v8 | Câncer de Próstata Estágio IVA AJCC (American Joint Committee on Cancer) v8 | Câncer de Próstata Estágio IVB AJCC (American Joint Committee on...Estados Unidos
-
Postgraduate Institute of Medical Education and...ConcluídoCharcot Articulação do PéÍndia
-
Bispebjerg HospitalConcluído
-
Cairo UniversityConcluído
-
Centre Hospitalier Universitaire de NīmesRecrutamentoCharcot Articulação do Pé | OsteoartropatiaFrança
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Ativo, não recrutandoAdenocarcinoma de próstata estágio III AJCC v7 | Adenocarcinoma de próstata estágio II AJCC v7 | Adenocarcinoma de Próstata Estágio I American Joint Committee on Cancer (AJCC) v7Estados Unidos
-
Jonsson Comprehensive Cancer CenterRetiradoAdenocarcinoma de próstata | Câncer de Próstata Estágio II AJCC v8 | Câncer de Próstata Estágio IIC AJCC v8 | Câncer de Próstata Estágio IIA AJCC v8 | Câncer de Próstata Estágio IIB AJCC v8 | Estágio I do Câncer de Próstata American Joint Committee on Cancer (AJCC) v8Estados Unidos
-
Bispebjerg HospitalH. Lundbeck A/S; Steno Diabetes Center Copenhagen; The Danish Diabetes Association e outros colaboradoresDesconhecidoPé diabético | Charcot JointDinamarca
-
Jonsson Comprehensive Cancer CenterMiraDXAtivo, não recrutandoAdenocarcinoma de próstata | Câncer de Próstata Estágio II AJCC v8 | Câncer de Próstata Estágio IIC AJCC v8 | Câncer de Próstata Estágio IIA AJCC v8 | Câncer de Próstata Estágio IIB AJCC v8 | Estágio I do Câncer de Próstata American Joint Committee on Cancer (AJCC) v8Estados Unidos
Ensaios clínicos em Febuxostate
-
Bio-innova Co., LtdAinda não está recrutandoSujeitos Saudáveis
-
Jiangsu HengRui Medicine Co., Ltd.Ainda não está recrutandoGota com hiperuricemia em adultos
-
TakedaConcluído
-
Sun Yat-sen UniversityDesconhecido
-
Eisai Co., Ltd.Concluído
-
Jiangsu HengRui Medicine Co., Ltd.Desconhecido
-
AstraZenecaConcluídoDiabetes tipo 2 | Albuminúria | HiperuricemiaEstados Unidos
-
TakedaConcluídoGota | Insuficiência Renal ModeradaEstados Unidos
-
TakedaConcluídoVoluntários SaudáveisEstados Unidos
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouDesconhecido